| abstract |
Oncogenic forms of Ras protein have been reported to occur in a variety of human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. Active forms of Ras protein which are complexed with GTP can bind to GTPase activating protein (GAP). This binding is thought to be an important step in the cell transforming activity of Ras. According to the present invention a group of peptides have been discovered which block the binding of Ras to GAP. |